F&P sees high, single-digit boost from recent mask launches
By HME News Staff
Updated 11:05 AM CDT, Tue May 26, 2026
AUCKLAND, New Zealand – Fisher & Paykel Healthcare reported revenue of $802.7 million for the 2026 financial year for its Homecare product group, an 8% increased compared to the previous year.
Revenue from obstructive sleep apnea (OSA) masks was up 7%.
“Our latest mask ranges, the F&P Solo and F&P Nova, continued to drive OSA mask growth,” said Lewis Gradon, managing director and CEO. “Our newest offering, the F&P Nova Nasal, was launched in the United States this past January to a positive reception.”
F&P reported total operating revenue of $2.31 billion, a 14% increase, and net profit after tax of $468.5 million, a 25% increase.
For the Hospital product group, the company reported revenue of $1.5 billion, an 18% increase. Sales from hospital consumables were up 16%.
“Our Hospital business performed strongly across the portfolio of therapies globally,” Gradon said. “We were especially encouraged by consumables growth, given it occurred during a period in which hospital admissions for seasonal respiratory illnesses in the United States and other major markets appeared to be subdued compared to the previous year. This suggests that changing clinical practice continues to be a strong growth driver.”
F&P expects the following performance for the 2027 financial year:
- Operating revenue to be in the range of approximately $2.45 billion to $2.57 billion; and
- Net profit after tax to be in the range of approximately $500 million to $550 million.
Related: F&P raises guidance.
Comments